MedDataX Logo

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

NCT ID: NCT00047541

Last Updated: 2008-08-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2001-02-28

Study Completion Date

2003-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69

NCT00047515

Open-Angle Glaucoma Ocular Hypertension
COMPLETED PHASE3

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41

NCT00047528

Open-Angle Glaucoma Ocular Hypertension
COMPLETED PHASE3

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients

NCT00069719

Open-Angle Glaucoma Ocular Hypertension
COMPLETED PHASE2

A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular Hypertension

NCT00051194

Glaucoma, Open-angle Ocular Hypertension
COMPLETED PHASE2

Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00761709

Open-Angle Glaucoma Ocular Hypertension
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open-Angle Glaucoma Ocular Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Alcon Investigational Agent

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension; visual acuity of 20/80 to 20/400 or better (Snellen equivalent) or logMAR visual acuity not worse than 0.6.

Exclusion Criteria

Clinically relevant ophthalmic or systemic conditions may be excluded.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alcon Research

INDUSTRY

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Trial Sites

Fort Worth, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C-01-70

Identifier Type: -

Identifier Source: secondary_id

C-01-70

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy
NCT01637246 COMPLETED
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients
NCT00069706 COMPLETED PHASE2
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00287521 COMPLETED PHASE2
A Phase II Study of AL-37807 to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00372931 COMPLETED PHASE2
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00314158 COMPLETED PHASE3
A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00061529 COMPLETED PHASE3
Comparison of the Alpha-2 Agonists for Prevention of Intraocular Pressure Elevation After Selective Laser Trabeculoplasty
NCT00567411 UNKNOWN NA
A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00311389 COMPLETED PHASE3
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00314171 COMPLETED PHASE3
Patient Preference Study
NCT00576342 COMPLETED PHASE3
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00326092 COMPLETED PHASE2
A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma
NCT02743780 COMPLETED PHASE1/PHASE2
Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C
NCT01312454 TERMINATED PHASE2
Safety and Efficacy of a Glaucoma Drug Delivery System
NCT00824720 COMPLETED PHASE2
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
NCT06666855 RECRUITING PHASE3
A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.
NCT00595101 COMPLETED PHASE2
AL-54478 Proof of Concept Study
NCT01318252 COMPLETED PHASE2
Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
NCT02136940 COMPLETED PHASE2
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
NCT05913232 COMPLETED PHASE2
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT03657797 COMPLETED PHASE2
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
NCT00333125 COMPLETED PHASE3
A Phase III Study of Travoprost/Timolol Combination in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00672997 COMPLETED PHASE3
Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension Patients
NCT00288951 COMPLETED PHASE3
A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension
NCT00788541 TERMINATED PHASE2
Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma
NCT01215786 COMPLETED PHASE1